The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Official Title: Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Study ID: NCT05819853
Brief Summary: Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.
Detailed Description: Polycystic ovary syndrome is one of the most common endocrinopathies in women, presents with anovulation in adolescence, and reproductive dysfunction is related to excess weight. After a 4-month observation period of either no medication or metformin treatment, females aged 12-35 years with obesity and polycystic ovary syndrome will receive 10 months of a glucagon-like peptide-1 receptor agonist to induce metabolic changes, weight loss and improve reproductive abnormalities. We will assess the relationship between weight loss and reproductive function, as well as identify if age, hormonal and metabolic measures and such insulin sensitivity and insulin secretion predict the response to glucagon-like peptide-1 receptor agonist therapy.
Minimum Age: 12 Years
Eligible Ages: CHILD, ADULT
Sex: FEMALE
Healthy Volunteers: No
University of Colorado Anschutz/Children's Hospital Colorado Aurora, Aurora, Colorado, United States
Name: Melanie Cree-Green, MD,PhD
Affiliation: University of Colorado Anschutz/Children's Hospital Colorado
Role: PRINCIPAL_INVESTIGATOR